When to Use Warfarin vs Apixaban
Apixaban should be your default anticoagulant for atrial fibrillation in most patients, but warfarin remains mandatory for mechanical heart valves and moderate-to-severe mitral stenosis. 1, 2
Absolute Indications for Warfarin (Use Warfarin, NOT Apixaban)
You must use warfarin in these situations:
- Mechanical heart valves - Apixaban and other DOACs are contraindicated 1, 2, 3
- Moderate-to-severe mitral stenosis (rheumatic heart disease) - DOACs showed worse outcomes in the INVICTUS trial 1, 2, 3
These are non-negotiable. The evidence shows DOACs perform worse or lack safety data in these populations.
Strong Preference for Warfarin
Consider warfarin over apixaban when:
- End-stage renal disease (ESRD) on dialysis - While recent data suggests apixaban may be cautiously used 2, 4, 5, guidelines recommend warfarin as first-line due to lack of robust trial evidence for DOACs in dialysis patients 2
- Antiphospholipid syndrome - Warfarin remains preferred based on available evidence 6
- Extreme obesity (>120-150 kg or BMI >40) - Though emerging data suggests apixaban may be safe 7, warfarin provides more reliable monitoring in this population 6
Clear Preference for Apixaban Over Warfarin
Switch from warfarin to apixaban or start apixaban when:
- Poor INR control - If time in therapeutic range (TTR) is <70%, switch to apixaban 1
- Risk of intracranial hemorrhage - Apixaban has significantly lower intracranial bleeding risk 1
- Patient preference for no monitoring - Apixaban requires no INR checks 8
- Reduced major bleeding risk - Meta-analyses show lower bleeding rates with apixaban 9, 10
- Polypharmacy concerns - Fewer drug interactions than warfarin 1
Apixaban Dosing Considerations
When using apixaban for atrial fibrillation, dose appropriately 8:
- Standard dose: 5 mg twice daily
- Reduced dose: 2.5 mg twice daily if patient has ≥2 of:
- Age ≥80 years
- Weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
Renal Impairment Algorithm
For CrCl 15-30 mL/min (Stage IV CKD):
- Apixaban 2.5 mg twice daily may be considered 2
- Warfarin remains guideline-recommended first choice 2
For ESRD on dialysis:
- Warfarin (INR 2.0-3.0) is guideline-recommended 2
- Apixaban may be cautiously considered based on emerging data showing similar safety 4, 5, but this is off-label
For CrCl <15 mL/min not on dialysis:
- Avoid dabigatran, rivaroxaban, edoxaban entirely 2
- Apixaban has most favorable renal profile among DOACs but still use warfarin as first-line 2
Critical Switching Considerations
When switching from warfarin to apixaban 8:
- Stop warfarin
- Start apixaban when INR <2.0
- Caution: Risk temporarily increases in first 60 days after switching 10
When switching from apixaban to warfarin 8:
- Start both parenteral anticoagulant AND warfarin at time of next apixaban dose
- Continue parenteral anticoagulant until INR therapeutic
- This is because apixaban affects INR measurements
Common Pitfalls to Avoid
- Don't use apixaban in mechanical valves - This caused increased thrombosis in trials 2, 3
- Don't underdose apixaban - Use 2.5 mg BID only if patient meets ≥2 dose-reduction criteria 8
- Don't combine with strong CYP3A4 + P-gp inhibitors (ketoconazole, itraconazole, ritonavir) without dose reduction 8
- Don't assume all DOACs are equivalent - Apixaban shows better outcomes than rivaroxaban when switching from warfarin 10
The Bottom Line Algorithm
- Check for absolute contraindications to apixaban (mechanical valve, moderate-severe mitral stenosis) → Use warfarin
- Check renal function: ESRD on dialysis → Prefer warfarin (apixaban possible but off-label)
- If on warfarin with poor INR control or high bleeding risk → Switch to apixaban
- For new atrial fibrillation diagnosis → Start apixaban unless contraindicated
- Reassess periodically - Renal function and bleeding risk change over time 1, 2
The 2024 ESC guidelines are explicit: DOACs like apixaban are preferred over warfarin for stroke prevention in atrial fibrillation, except in the specific contraindicated populations 1.